The annual ASCO GUCS 2016 conference was held in San Francisco, California from January 7-9. There was a number of exciting abstracts and research presented at this conference. A growing body of research has led to the development and approval of many agents in metastatic castrate resistant prostate cancer (mCRPC), and specialists face challenges regarding choice of therapy and sequencing of treatment options. For this reason, the focus of issue of CARE Perspectives is on prostate cancer. It provides a summary of the most compelling stories and news presented at ASCO GUCS, framed from a Canadian perspective.